Gyre Therapeutics (GYRE) Other Non Operating Income (2015 - 2026)

Gyre Therapeutics (GYRE) has 12 years of Other Non Operating Income data on file, last reported at $29000.0 in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $29000.0, down 72.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 million (up 5.44% YoY), and the FY2025 annual result was -$1.5 million, up 9.28% from the prior year.
• Other Non Operating Income climbed to $29000.0 in Q1 2026 per GYRE's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $858000.0 in Q4 2022 and troughed at -$2.2 million in Q4 2025.
• A 5-year average of -$185470.6 and a median of -$1000.0 in 2022 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income surged 4390.0% in 2022, then tumbled 133200.0% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at $858000.0 in 2022, then tumbled by 127.62% to -$237000.0 in 2023, then sank by 589.45% to -$1.6 million in 2024, then sank by 34.27% to -$2.2 million in 2025, then surged by 101.32% to $29000.0 in 2026.
• Business Quant data shows GYRE's Other Non Operating Income at $29000.0 in Q1 2026, -$2.2 million in Q4 2025, and $727000.0 in Q3 2025.